RLMD (Relmada Therapeutics) היקף יתרות המזומנים של החברה

Relmada Therapeutics (RLMD) minimizes capital expenditures by outsourcing production and testing to external partners. The company's remaining cash balance visualizes this strategy, where the 0.20 level reflects the current magnitude of liquidity. Business protection is based on patents for the side-effect-free drug esmetadone, however, the high burn rate makes the company dependent on the success of its R&D pipeline.
פילוחים אנליטיים של חברת Relmada Therapeutics

This metric captures the volume of liquid assets, allowing for an assessment of the company's ability to fund operating activities without resorting to external borrowing. By analyzing the level of cash reserves, a conservative investor can confirm the resilience of Relmada Therapeutics (RLMD) in implementing ethical ESG standards during the development of neuropsychiatric drugs, which minimizes financial risks in the long term and guarantees transparency in capital management.